drugset / Trial / NCT03717454
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
Unknown
50 enrolled
Zhebao Wu
Beijing Tiantan Hospital · collabChinese PLA General Hospital · collabFirst Affiliated Hospital of Fujian Medical University · collabFirst Affiliated Hospital of Wenzhou Medical University · collabFirst Hospital of China Medical University · collabHuashan Hospital · collabPeking Union Medical College Hospital · collabXinqiao Hospital of Chongqing · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2021-12-30
- Completion
- 2022-01-31
Publications
- Results Mukherjee J, Majji D, Kaur J, Constantinescu CC, Narayanan TK, Shi B, Nour MT, Pan ML. PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. Synapse. 2017 Mar;71(3):10.1002/syn.21950. doi: 10.1002/syn.21950. Epub 2016 Nov 30.
- Results Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692.
- Results Schonitzer V, Haasters F, Kasbauer S, Ulrich V, Mille E, Gildehaus FJ, Carlsen J, Pape M, Beck R, Delker A, Boning G, Mutschler W, Bocker W, Schieker M, Bartenstein P. In vivo mesenchymal stem cell tracking with PET using the dopamine type 2 receptor and 18F-fallypride. J Nucl Med. 2014 Aug;55(8):1342-7. doi: 10.2967/jnumed.113.134775. Epub 2014 Jul 14.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bromocriptine | Small molecule | 7.5 mg | — |
| Subject | Cabergoline | Small molecule | 2 mg | — |